Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirisudanol
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pirisudanol is a psychostimulant and nootropic agent that is chemically a succinic acid ester of pyridoxine (Vitamin B6) and deanol (dimethylaminoethanol). It is primarily used to treat cognitive deficits, age-related mental decline, and cerebrovascular disorders. By acting as a precursor to acetylcholine and providing pyridoxine, it enhances cerebral metabolism and cholinergic neurotransmission. It has been marketed in several European countries under brand names like Stivane and Mentis.
- Brand names
- StivaneMentisNadexPridana
- Other names
- PyrisudanolPirisudanolumDeanol pyridoxine succinatePyridoxine deanol succinate
Beyond the preview
Go deeper on pirisudanol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirisudanol.